Gene Therapy Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Gene Therapy Market Overview

The market is rapidly expanding, driven by advancements in genetic engineering, viral and non-viral vector technologies, and the increasing prevalence of rare and inherited diseases. Rising regulatory approvals, growing R&D investments, and improved clinical trial success rates are accelerating adoption. Innovative treatments targeting oncology, genetic disorders, and rare diseases are shaping the market, supporting long-term growth globally. The market reached a value of approximately USD 9.59 Billion in 2025.

Gene Therapy Market Growth Drivers

Regulatory Support Driving Rare Disease Treatment Market Expansion

Rising demand for innovative treatments and strong regulatory backing are fueling gene therapy adoption. For instance, in April 2026, the FDA accepted Ultragenyx’s resubmitted Biologics License Application for UX111 targeting Sanfilippo syndrome Type A, a rare disorder. This milestone underscores ongoing progress in rare disease gene therapy, encouraging investment, accelerating clinical development, and supporting market growth globally.

Gene Therapy Market Trends

Key trends shaping the market include rising rare disease focus, regulatory support, advanced therapies, and gene editing innovations.

Breakthrough Designations Enhancing Market Development

Growing focus on advanced therapies and increasing R&D investments drive market evolution. For instance, in March 2026, MeiraGTx’s AAV2‑hAQP1 gene therapy for radiation-induced xerostomia received FDA Breakthrough Therapy Designation. This regulatory recognition of gene augmentation solutions boosts innovation, validates clinical potential, and strengthens long-term development opportunities across the market.

Gene Therapy Market Segmentation

Gene Therapy Market Share

Viral Vectors Expected to Dominate the Market Segment by Vector Type

By vector type, viral vectors dominated the segment in the historical period, accounting for over 74% of the total market share. The preference for viral vectors is driven by their high efficiency in gene transfer, established clinical success, and versatility across multiple indications. This dominance highlights the ongoing reliance on proven delivery systems to accelerate gene therapy development globally.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Gene Therapy Market Analysis by Region

North America captured approximately 41% of the market during the historical period. Strong regulatory support, high R&D investment, and early adoption of advanced treatments, including rare disease gene therapy, are key drivers. The region continues to lead in clinical trials, commercialization, and technology development, reinforcing its position in the global market.

Leading Players in the Gene Therapy Market

Other key players in the market are Sibiono GeneTech Co. Ltd., Gilead Sciences, Inc., Sangamo Therapeutics, Inc., Intellia Therapeutics, Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Sio Gene Therapies Ltd., Ultragenyx Pharmaceutical Inc., Krystal Biotech, Inc., Rocket Pharmaceuticals, Ltd., MeiraGTx Limited., Solid Biosciences Inc., GenSight Biologics S.A., Editas Medicine, Inc., CRISPR Therapeutics AG, Spark Therapeutics, Inc., Genprex, Inc., Poseida Therapeutics, Inc., Astellas Pharma Inc., Voyager Therapeutics, Inc., Coave Therapeutics, Precision BioSciences, Inc., and others.

Key Questions Answered in the Gene Therapy Market Report

• What was the gene therapy market value in 2025?
• What is the gene therapy market forecast outlook for 2026-2035?
• What major factors aid the demand for the gene therapy market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major gene therapy market trends?
• Which indication is expected to dominate the market segment?
• Which vector is expected to dominate the market segment?
• Who are the key players in the gene therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?